Advantage Alpha Capital Partners LP Has $383,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Advantage Alpha Capital Partners LP decreased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 34.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 24,914 shares of the biopharmaceutical company’s stock after selling 13,160 shares during the period. Advantage Alpha Capital Partners LP’s holdings in ACADIA Pharmaceuticals were worth $383,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. M&G Plc increased its holdings in ACADIA Pharmaceuticals by 12.4% in the second quarter. M&G Plc now owns 351,115 shares of the biopharmaceutical company’s stock valued at $5,618,000 after purchasing an additional 38,790 shares during the last quarter. Fred Alger Management LLC grew its position in shares of ACADIA Pharmaceuticals by 19.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company’s stock worth $43,947,000 after buying an additional 446,875 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at about $483,000. US Bancorp DE raised its position in shares of ACADIA Pharmaceuticals by 2,084.0% in the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 31,426 shares during the period. Finally, Sei Investments Co. boosted its stake in ACADIA Pharmaceuticals by 6.2% during the 1st quarter. Sei Investments Co. now owns 34,752 shares of the biopharmaceutical company’s stock worth $642,000 after acquiring an additional 2,034 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $16.21 on Wednesday. The stock’s 50-day simple moving average is $15.62 and its 200 day simple moving average is $15.98. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $32.59. The company has a market cap of $2.70 billion, a P/E ratio of 20.78 and a beta of 0.38.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.06. The firm had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business’s quarterly revenue was up 18.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.40) EPS. As a group, equities analysts predict that ACADIA Pharmaceuticals Inc. will post 0.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ACAD. UBS Group lowered their target price on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Cantor Fitzgerald dropped their price objective on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Citigroup decreased their target price on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada dropped their price target on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, Morgan Stanley lowered ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $28.00 to $20.00 in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.56.

Insiders Place Their Bets

In other news, CFO Mark C. Schneyer sold 10,259 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $172,453.79. Following the transaction, the chief financial officer now directly owns 53,302 shares in the company, valued at $896,006.62. The trade was a 16.14 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider James Kihara sold 4,073 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares of the company’s stock, valued at $333,897.03. This trade represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,661 shares of company stock valued at $414,551. 28.30% of the stock is currently owned by corporate insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.